Background {#Sec1}
==========

Osteosarcoma is a primary malignant tumor originating from mesenchymal tissue. The annual incidence is similar worldwide, ranging from 1 to 4 in 1 million. Although the overall incidence of osteosarcoma is not high, it is the most common type of bone and soft tissue tumors, accounting for 40.51% of primary malignant bone tumors. With improvements in limb salvage surgery and neoadjuvant chemotherapy, the 5-year survival rate of non-metastatic patients is about 65--70% \[[@CR1]\]. Unfortunately, distant metastases are found in about 20% of patients, 90% of which are lung metastases \[[@CR2]\]. Once distant metastasis occurs, the 5-year survival rate is only 15--30% \[[@CR3]--[@CR5]\]. However, the mechanisms of osteosarcoma metastasis are still largely unknown.

In recent years, bioinformatics has been widely used to reveal tumor progression and the internal mechanism of carcinogenesis at the genome level for many cancer types. In particular, there are many bioinformatics web tools that can help us analyze relevant data, with standardized and visual results. Although microarray data for osteosarcoma are still limited, some hidden and interesting information like the expression of key genes \[[@CR6]--[@CR8]\], microRNAs \[[@CR9]\] and co-expression modules \[[@CR10]\] in osteosarcoma and drug resistance in osteosarcoma patients \[[@CR11]\] could be found.

In this study, a series of mRNA data was analyzed to obtain differentially expressed genes (DEGs) between osteosarcoma patients that did, or did not, develop metastases. Subsequently, a protein-protein interaction (PPI) network of the DEGs was constructed. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, and survival analysis were used to identify candidate genes. Furthermore, we analyzed function predictions, different expression in normal and malignant human tissues, and immune infiltration analysis of the candidate genes to confirm their function and distribution. In conclusion, 24 DEGs and three candidate genes were identified.

Methods {#Sec2}
=======

Identification of DEGs and PPI network construction {#Sec3}
---------------------------------------------------

A public series submitted by Buddingh et al. in 2011, GSE21257 \[[@CR12]\], was downloaded from the Gene Expression Omnibus database (GEO, <http://www.ncbi.nlm.nih.gov/geo>, RRID: SCR_005012) \[[@CR13]\]. The series contains 53 pre-chemotherapy biopsy samples from osteosarcoma patients that developed metastases (*n* = 34) and that did not develop metastases within 5 yrs. (*n* = 19). The biopsy tissue contained the tumor cells and microenvironment around the tumor. All the expression data were analyzed via the R language (version 3.5.1) BIOCONDUCTOR package, and the DEGs were screened using the LIMMA package at a statistical significance Benjamini and Hochberg false discovery rate-adjusted *p*-value cutoff of 0.05 and an absolute value of fold change greater than 2. The online Search Tool for the Retrieval of Interacting Genes (STRING, <http://string-db.org>, RRID: SCR_005223) \[[@CR14]\] is a database of known and predicted protein-protein interactions. We used STRING to find observed co-expression of the DEGs in humans and constructed a PPI network of the DEGs with statistical significance of interaction scores \> 0.4 (medium confidence score).

GO and pathway enrichment {#Sec4}
-------------------------

The GO and KEGG pathway enrichment analyses were performed using DAVID (<https://david.ncifcrf.gov/>, RRID: SCR_001881) \[[@CR15]\]. The biological process (BP) analysis, cellular component (CC) analysis, molecular function (MF) analysis \[[@CR16]\], and KEGG \[[@CR17]\] pathway enrichment analysis of the DEGs were carried out and *p*-values \< 0.05 were considered to indicate statistical significance. Moreover, a biological process analysis of the hub genes was constructed and visualized using the Biological Networks Gene Ontology tool (BiNGO, RRID: SCR_005736) \[[@CR18]\] plugin of Cytoscape (version 3.6.1, RRID: SCR_003032) \[[@CR19]\].

Survival analysis of the DEGs {#Sec5}
-----------------------------

PROGgeneV2 (<http://genomics.jefferson.edu/proggene>) \[[@CR20]\] is a tool that can be used with publicly available data to study the prognostic implications of genes. All the DEGs were input into the database separately and overall survival plots (Kaplan Meier, KM plots) were created based on the cohort divided at the median of the given gene expression. PROGgeneV2 uses the SURVIVAL package of R for the hypothesis test. The DEGs that had *p*-values \< 0.05 were considered as candidate genes and were analyzed further.

Function predictions of the candidate genes {#Sec6}
-------------------------------------------

GeneMANIA (<http://www.genemania.org>, RRID: SCR_005709) \[[@CR21]\] is a flexible, user-friendly open-source tool. Besides constructing the PPI network, the web tool can display an interactive functional association network, illustrating the relationships among genes. The advanced statistical options used were max resultant genes = 20, max resultant attributes = 10, and the automatically selected network weighting method. These analyses were conducted using the *Homo sapiens* database.

Different expression of candidate genes in normal and malignant human tissues {#Sec7}
-----------------------------------------------------------------------------

The SAGE Anatomic Viewer, part of the online Serial Analysis of Gene Expression database (SAGE, <http://www.ncbi.nlm.nih.gov/SAGE>, RRID: SCR_000796) \[[@CR22]\], was used to display candidate gene expression in normal and malignant human tissues. The related expression levels were based on the analysis of counts of SAGE tags, ordered by color.

Immune infiltration analysis of the candidate genes {#Sec8}
---------------------------------------------------

Tumor IMmune Estimation Resource (TIMER, <https://cistrome.shinyapps.io/timer/>) \[[@CR23]\] is a comprehensive web server for systematic analysis of immune infiltrates across diverse cancer types. When we input the candidate gene symbols for at least one cancer type, scatterplots were generated and displayed showing the purity-corrected partial Spearman's correlations and statistical significance. Tumor purity is expected to have negative associations with high levels of expression in the microenvironment, while the opposite is true for the tumor cells. Unfortunately, there is no available data for osteosarcoma, so we chose SARC (sarcoma), OV (ovarian serous cystadenocarcinoma), LUSC (lung squamous cell carcinoma), LIHC (liver hepatocellular carcinoma), and BRCA (breast invasive carcinoma) as the multi-cancer types.

Results {#Sec9}
=======

Identification of DEGs and PPI network construction {#Sec10}
---------------------------------------------------

Only 24 downregulated DEGs were recognized in the osteosarcoma patients that developed metastases, and no upregulated genes were found in the profiles (Fig. [1](#Fig1){ref-type="fig"}a), meaning that the DEGs protect patients from metastases. Detailed information for the DEGs is shown in Table [1](#Tab1){ref-type="table"}. The co-expressed DEGs in humans are shown in Fig. [1](#Fig1){ref-type="fig"}b. The PPI network of the DEGs is shown in Fig. [1](#Fig1){ref-type="fig"}c. Fig. 1Volcano plot, observed co-expressed genes, protein-protein interaction (PPI) network, and biological process analysis of DEGs. The DEGs were screened with criteria of *p* \< 0.01 and absolute value logFC (fold change) \> 1; the red dots represent downregulated genes and the blue dots represent unchanged genes (**a**). The observed co-expressed genes of DEGs in *Homo sapiens* are shown in triangular matrices; the intensity of color indicates the level of confidence that two proteins are functionally associated (**b**). The PPI network of the DEGs; the network nodes represent proteins and the edges represent the protein-protein associations (**c**). Biological process analysis of the DEGs was performed and visualized using BiNGO; the color depth of the nodes refers to the corrected *p* values of the ontologies (**d**) Table 1The statistical metrics for the DEGsIllumina Probe IDGene SymbollogFC*p*-valueFDRt-valueFull name0003120608AIF1−1.21552.66E-050.027581− 4.60773Allograft inflammatory factor 10006900465ALOX5−1.14678.39E-050.041468−4.26677Arachidonate 5-lipoxygenase0004180411ALOX5AP−1.508135.14E-070.008347− 5.72697Arachidonate 5-lipoxygenase activating protein0000580603AMICA1−1.113258.96E-050.041468−4.24687Junction adhesion molecule like0004010301C1orf162−1.002840.0001230.047543−4.15122Chromosome 1 open reading frame 1620004390370C1QA−1.296218.78E-050.041468−4.25276Complement C1q A chain0000990398CD14−1.310534.20E-050.034058−4.47365CD14 molecule0003420154CD74−1.493372.02E-050.027581−4.68835CD74 molecule0000010215CD86−1.143465.97E-060.01725−5.03952CD86 molecule0002100100FCGR2A−1.124342.10E-060.017075−5.33441Fc fragment of igg receptor iia0005820008FGL2−1.222643.46E-060.01725−5.19438Fibrinogen like 20007650441FHL2−1.03948.64E-050.041468−4.2578Four and a half LIM domains 20004150593FPRL2−1.097451.19E-050.021461−4.84176Formyl peptide receptor 30005080193GIMAP4−1.00987.16E-050.040544−4.31433Gtpase, IMAP family member 40007200180HCLS1−1.062925.44E-050.036314−4.39632Hematopoietic cell-specific Lyn substrate 10007400685HCST−1.196295.03E-050.035478−4.42004Hematopoietic cell signal transducer0007400136HLA-DMA−1.315316.25E-060.01725−5.02628Major histocompatibility complex, class II, DM alpha0005870743HLA-DMB−1.234155.05E-060.01725−5.0869Major histocompatibility complex, class II, DM beta0006560088HLA-DOA−1.086984.89E-060.01725−5.09634Major histocompatibility complex, class II, DO alpha0006480500HLA-DPA1−1.47192.18E-050.027581−4.66677Major histocompatibility complex, class II, DP alpha 10006290561HLA-DQA1−1.604344.70E-050.034712−4.44Major histocompatibility complex, class II, DQ alpha 10001440296HLA-DQB1−1.323280.0001410.04985−4.10794Major histocompatibility complex, class II, DQ beta 10002680370HLA-DRA−1.486121.52E-050.024614−4.77169Major histocompatibility complex, class II, DR alpha0006040379HLA-DRB4−1.595883.18E-050.03033−4.55585Major histocompatibility complex, class II, DR beta 4

GO and pathway enrichment {#Sec11}
-------------------------

The results of the biological classification of the DEGs, and functional and pathway enrichment analyses are shown in Fig. [2](#Fig2){ref-type="fig"} (details are shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). The results of the biological process analysis of the DEGs is shown in Fig. [1](#Fig1){ref-type="fig"}d. GO analysis showed that in the BP ontology (Fig. [2](#Fig2){ref-type="fig"}a), immune response (10 genes) and T cell co-stimulation (6 genes) constituted the most significantly enriched terms. In the CC ontology (Fig. [2](#Fig2){ref-type="fig"}b), the most significantly enriched terms were involved in MHC class II protein complex (9 genes) and the lysosomal membrane (9 genes). In the MF ontology (Fig. [2](#Fig2){ref-type="fig"}c), the most significantly enriched terms were involved in MHC class II receptor activity (7 genes), MHC class II protein complex binding (5 genes), and peptide antigen binding (5 genes). In the KEGG pathways (Fig. [2](#Fig2){ref-type="fig"}d), the most significantly enriched terms were shown as tuberculosis (11 genes) and systemic lupus erythematosus (11 genes). Fig. 2GO and KEGG pathway enrichment analyses of the DEGs including biological process (**a**), cellular component (**b**), and molecular function (**c**). Functional and pathway enrichment analyses were performed using DAVID (**d**). The size of the dots represents the gene count and the color depth of the dots represents the -log (*p*-value) Table 2The top 5 enriched GO terms of the DEGsCategoryGO IDGO TermCountFDRLog PGenesBiological Process0002504antigen processing and presentation of peptide or polysaccharide antigen via MHC class II81.62E-14−16.8846HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRABiological Process0019886antigen processing and presentation of exogenous peptide antigen via MHC class II95.29E-11−13.369HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DQA1, HLA-DRABiological Process0019882antigen processing and presentation73.03E-08−10.6113HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, CD74, HLA-DQA1, HLA-DRABiological Process0006955immune response103.29E-07−9.57522HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DQA1, HLA-DRABiological Process0002503peptide antigen assembly with MHC class II protein complex41.52E-05−7.91138HLA-DRB4, HLA-DMB, HLA-DMA, HLA-DRACellular Component0042613MHC class II protein complex92.13E-16−18.6699HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DQA1, HLA-DRACellular Component0071556integral component of lumenal side of endoplasmic reticulum membrane61.41E-07−9.84824HLA-DQB1, HLA-DRB4, HLA-DPA1, CD74, HLA-DQA1, HLA-DRACellular Component0005765lysosomal membrane94.03E-07−9.39244HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DQA1, HLA-DRACellular Component0030658transport vesicle membrane65.93E-07−9.2251HLA-DQB1, HLA-DRB4, HLA-DPA1, CD74, HLA-DQA1, HLA-DRACellular Component0030669clathrin-coated endocytic vesicle membrane68.83E-07−9.05199HLA-DQB1, HLA-DRB4, HLA-DPA1, CD74, HLA-DQA1, HLA-DRAMolecular Function0032395MHC class II receptor activity75.72E-12−14.2221HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAMolecular Function0023026MHC class II protein complex binding52.47E-06−8.58782HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DRAMolecular Function0042605peptide antigen binding52.75E-05−7.54062HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DQA1, HLA-DRAMolecular Function0004051arachidonate 5-lipoxygenase activity22.237376−2.62558ALOX5AP, ALOX5 Table 3The enriched KEGG pathway terms of the DEGsPathway IDPathway NameGene CountFDRLogPGeneshsa05150*Staphylococcus aureus* infection106.33E-13−15.21HLA-DQB1, C1QA, HLA-DRB4, HLA-DPA1, FCGR2A, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05332Graft-versus-host disease91.37E-12−14.85HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05330Allograft rejection93.67E-12−14.41HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa04940Type I diabetes mellitus91.11E-11−13.93HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa04672Intestinal immune network for IgA production92.96E-11−13.50HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05322Systemic lupus erythematosus113.85E-11−13.39HLA-DQB1, C1QA, CD86, HLA-DRB4, HLA-DPA1, FCGR2A, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05320Autoimmune thyroid disease97.06E-11−13.13HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05310Asthma81.49E-10−12.80HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05416Viral myocarditis91.54E-10−12.79HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05152Tuberculosis116.54E-10−12.16HLA-DQB1, HLA-DRB4, HLA-DPA1, FCGR2A, HLA-DMB, HLA-DOA, HLA-DMA, CD14, CD74, HLA-DQA1, HLA-DRAhsa05140Leishmaniasis99.79E-10−11.98HLA-DQB1, HLA-DRB4, HLA-DPA1, FCGR2A, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa04612Antigen processing and presentation91.73E-09−11.74HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DQA1, HLA-DRAhsa05323Rheumatoid arthritis95.81E-09−11.21HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa04145Phagosome108.33E-09−11.06HLA-DQB1, HLA-DRB4, HLA-DPA1, FCGR2A, HLA-DMB, HLA-DOA, HLA-DMA, CD14, HLA-DQA1, HLA-DRAhsa05145Toxoplasmosis93.62E-08−10.42HLA-DQB1, HLA-DRB4, HLA-DPA1, ALOX5, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05321Inflammatory bowel disease (IBD)84.36E-08−10.34HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa04514Cell adhesion molecules (CAMs)92.86E-07−9.52HLA-DQB1, CD86, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05168Herpes simplex infection92.18E-06−8.64HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, CD74, HLA-DQA1, HLA-DRAhsa05164Influenza A85.24E-05−7.26HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05166HTLV-I infection87.01E-04−6.13HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DMB, HLA-DOA, HLA-DMA, HLA-DQA1, HLA-DRAhsa05169Epstein-Barr virus infection50.13728−3.84HLA-DQB1, HLA-DRB4, HLA-DPA1, HLA-DQA1, HLA-DRAhsa04640Hematopoietic cell lineage314.8897−1.77HLA-DRB4, CD14, HLA-DRA

Survival analysis of the DEGs {#Sec12}
-----------------------------

Among the 24 DEGs, overall survival plots were obtained for 15 genes, as shown in Fig. [3](#Fig3){ref-type="fig"}. The high expression group of 15 DEGs would have better survival than the low expression group. However, only three of these were significant (\< 0.05), namely ALOX5AP, CD74, and FCGR2A. These were selected as the candidate genes for further analyses. The gene expression of the candidate genes could be found in the Additional file [1](#MOESM1){ref-type="media"}: Table S1. Fig. 3Survival curves of DEGs were created using the Kaplan-Meier curve in the PROGgeneV2 online platform; the red line represents the high expression of the gene and the green line represents the low expression of the gene

Function predictions for the candidate genes {#Sec13}
--------------------------------------------

An interactive functional association network constructed by GeneMANIA revealed correlations among genes for the candidate genes. The gene set enriched for ALOX5AP is responsible mainly for eicosanoid and fatty acid derivative biosynthetic processes (Fig. [4](#Fig4){ref-type="fig"}a). Meanwhile, the gene set enriched for CD74 is responsible mainly for positive regulation of lymphocyte activation and leukocyte activation (Fig. [4](#Fig4){ref-type="fig"}b), and the gene set enriched for FCGR2A is responsible for immune response-regulating cell surface receptor signaling pathways, and Fc receptor signaling pathways (Fig. [4](#Fig4){ref-type="fig"}c). Moreover, the gene set enriched for the three genes is responsible mainly for antigen processing and presentation of exogenous peptide antigens via MHC class II, antigen processing, and presentation of peptide antigens via MHC class II (Fig. [4](#Fig4){ref-type="fig"}d). Compared to the functional analyses of the DEGs, the enriched functions of the candidate genes also have their own characteristics. Fig. 4Protein-protein interaction network of ALOX5AP (**a**), CD74 (**b**), and FCGR2A (**c**) candidate genes (**d**). Different colors of the network edges indicate the bioinformatics method applied; the different colors for the network nodes indicate the biological functions of the set of enrichment genes

Different expression of candidate genes in normal and malignant human tissues {#Sec14}
-----------------------------------------------------------------------------

The expression profiles of the three candidate genes in human tissue were displayed using SAGE. As shown, ALOX5AP mRNA in lung, liver, breast, peritoneum, and lymph node tissues displayed higher levels than in the matched cancer tissues (Fig. [5](#Fig5){ref-type="fig"}a). CD74 mRNA in brain, retina, lung, and lymph nodes displayed higher levels than in the matched cancer tissues (Fig. [5](#Fig5){ref-type="fig"}b), while FCGR2A mRNA in thyroid, lung, kidney, peritoneum, and lymph node tissues displayed higher levels than in the matched cancer tissues (Fig. [5](#Fig5){ref-type="fig"}c). All the candidate genes were expressed at higher levels in lung and lymph node tissues than in the matched cancer tissues. Fig. 5Expression profiles for ALOX5AP (**a**), CD74 (**b**), and FCGR2A (**c**) in human cancers analyzed using SAGE. The left side represents normal tissues and the right side represents the matched cancer tissues. The related expression levels are based on the analysis of counts of SAGE tags, ordered by ten colors

Immune infiltration analysis of the candidate genes {#Sec15}
---------------------------------------------------

In the five cancer types we selected, the expression levels of the three candidate genes were all negatively associated with tumor purity (Fig. [6](#Fig6){ref-type="fig"}). It can be inferred from this result that all three candidate genes are probably expressed in the microenvironment, not in the tumor cells. Fig. 6Immune infiltration of ALOX5AP (A), CD74 (B), and FCGR2A (C) in different cancer types, such as SARC (sarcoma), OV (ovarian serous cystadenocarcinoma), LUSC (lung squamous cell carcinoma), LIHC (liver hepatocellular carcinoma), and BRCA (breast invasive carcinoma)

The data that support the findings of this study were generated at GSE21257 \[[@CR12]\] in GEO. Derived data supporting the findings of this study are available from the corresponding author on request.

Discussion {#Sec16}
==========

Osteosarcoma metastasis is a complex process of interaction between multiple genes and multiple signaling pathways in tumor cells and stromal cells. The deletion of the p53 gene and activation of the Notch pathway in osteosarcoma cells may contribute to invasion and metastasis \[[@CR24]\]. Induction of Src-family tyrosine kinase (SFK) and the synergy of metal matrix protease-2, 9 (MMPs-2, 9), may help osteosarcoma cells degrade the extracellular matrix and enter the blood circulation by activating the Wnt/beta-catenin signaling pathway \[[@CR25]\]. Meanwhile, SFK activates PI3K/AKT and Ras/MAPK signaling pathways to avoid apoptosis in osteosarcoma cells \[[@CR26]\].

Buddingh et al. first reported the series in 2011 \[[@CR12]\] which we analyzed in this study. They also compared patients that did, or did not, develop metastases within 5 years and identified 14 upregulated and 118 downregulated genes in patients that developed metastases, with an only statistical criterion of adjust *p* \< 0.05. Buddingh proved that these genes were expressed by tumor stroma and not by tumor cells by experiment. Almost half of these genes were attributed to macrophage function. Furthermore, the authors proposed that tumor-associated macrophages (TAM) in the tumor-microenvironment have an antimetastatic effect, which can improve survival in osteosarcoma.

This is a notable work. However, the considered statistical criteria was just only the *p*-value and may produce some false-positive results. Meanwhile, the authors focused on the antimetastatic function of TAM and provided a detailed argument to support this. They did not identify the key molecules played a role in this process which would be benefit for future researchers. In our study, only 24 downregulated DEGs were recognized with a statistical significance of adjust *p* \< 0.05 and absolute value of fold change \> 2. These DEGs have greater statistical significance than those in the previous study. Besides that, we proposed three prognostic candidate genes would play an important role in the patients who did develop metastases within 5 years.

GO and KEGG pathway enrichment analyses revealed that changes in the DEGs mainly occurred in the MHC class II protein complex, immune response, and antigen processing and presentation. In other words, immune infiltrates or immune responses in the local microenvironment play an important role in osteosarcoma metastasis. Previous studies have reported that during metastasis, tumor-infiltrating lymphocytes (TILs) can be detected at a higher level than in normal tissue \[[@CR27]\], and patients with higher T-lymphocyte infiltration showed improved survival \[[@CR28], [@CR29]\]. It was proposed that some portion of the T-cells (like TILs) would act against tumor cells with a higher specific immunological reactivity than the non-infiltrating lymphocytes \[[@CR27]\]. Moreover, programmed cell death protein 1(PD-1) showed increased expressed in TIL \[[@CR30]\] and peripheral CD4^+^ and CD8^+^ T-lymphocytes \[[@CR31]\] Based on this result, the inhibition of the PD-1/PDL-1 interaction would lead to a decreased tumor burden in osteosarcoma-bearing mice \[[@CR32]\]. Overall, these theories are in agreement with our results.

Three candidate genes with prognostic value---namely ALOX5AP, CD74, and FCGR2A---were discovered. Interestingly, all the candidate genes showed higher expression in lung and lymph node tissues than in the matched cancer tissues and were probably expressed in the microenvironment, not in the tumor cells. This result is consistent with that of previous studies; the candidate genes are reportedly linked to tumor cells. The change in ALOX5AP expression can cause oxidative stress, which has some effects on human leukemia \[[@CR33]\]. Codreanu et al. reported that ALOX5AP could be a noninvasive candidate biomarker for lung cancer with global and targeted proteomics \[[@CR34]\]. Knights et al. identified ALOX5AP as associated with the pharmacokinetics of gemcitabine, which is an approved anti-cancer drug \[[@CR35]\]. Meanwhile, high expression of CD74 would cause functional HLA class II processing in brain metastatic tumor cells, with a better prognosis \[[@CR36]\]. Figueiredo et al. reported that MIF-CD74 signaling regulates the antitumor immune response of macrophages and dendritic cells in metastatic melanoma \[[@CR37]\]. Ekmekcioglu et al. found that CD74 is associated with overall survival and recurrence-free survival in stage III melanoma, and could be a useful prognostic tumor marker \[[@CR38]\]. Furthermore, FCGR2A is reportedly associated with the pharmacodynamics of monoclonal antibodies in different cancer types, such as colorectal cancer \[[@CR39]\], breast cancer \[[@CR40]\], and metastatic squamous cell head and neck cancer \[[@CR41]\]. However, a search of the published literature revealed that there are few studies about the candidate genes for osteosarcoma. This observation suggests that the candidate genes may require further research to reveal the mechanisms of osteosarcoma metastasis.

This bioinformatics study provides information on the DEGs and candidate genes that protect osteosarcoma patients from metastasis, which could inform future research. However, we must recognize that the roles of the candidate genes are still unknown. Additional well-designed experiments and analyses are required to reveal these mechanisms. In addition, all the results from this study were obtained in silicon; in vivo and in vitro experiments are necessary to test the functions of these DEGs. A note that if we could include some critical details of the surrounding muscle tissue, we might better analyze the mechanism of osteosarcoma metastasis.

Conclusions {#Sec17}
===========

In conclusion, we identified 24 DEGs, of which three candidate genes may be involved in the processes that protect osteosarcoma patients from metastasis. The molecules we found are potential targets for future research on osteosarcoma immunity. Furthermore, our results contribute to the identified biomarkers for osteosarcoma metastasis.
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 {#Sec18}

**Additional file 1: Table S1.** The gene expression of the candidate genes.
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